Omeza develops and commercializes marine-derived collagen and lipid products for advanced wound care; its lead product, OCM, is an FDA-cleared drug-device wound matrix derived from marine lipids and cold-water fish peptides. OCM is applied to complex wounds and is described as reducing inflammation, disrupting bacterial biofilm, and supporting tissue regeneration as an alternative to traditional skin grafts. The company is already generating revenue through a nationwide commercial partnership while advancing clinical programs aimed at expanding reimbursement across major hard-to-heal wounds. Omeza plans to use the Series A proceeds to accelerate clinical trials, expand commercial capabilities, and build its clinical and real-world evidence base to support broader payer coverage. The company has recently strengthened its governance with new board appointments as it prepares for its next phase of institutional growth.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2026